A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion
Phase of Trial: Phase II
Latest Information Update: 21 Dec 2018
Price : $35 *
At a glance
- Drugs Risuteganib (Primary)
- Indications Macular degeneration
- Focus Therapeutic Use
- Sponsors Allegro Ophthalmics
- 13 Jul 2015 Primary endpoint has been met. (Release of Vitreo Macular Adhesion (VMA) by Optical Coherence Tomography (OCT)), as reported by an Allegro Ophthalmics media release.
- 13 Jul 2015 Top-line results published in the Allegro Ophthalmics Media Release.
- 23 Jun 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.